Business Overview: IGC Pharma, Inc. (NYSE American: IGC)

---

Executive Summary

IGC Pharma, Inc. is a Maryland-incorporated, clinical-stage pharmaceutical company founded in 2005 and headquartered in Potomac, Maryland, with a manufacturing and product-development facility in Vancouver, Washington. The company's stated mission is to improve the lives of people affected by Alzheimer's disease, and its entire pipeline is organized around that single therapeutic area, spanning agitation, cognition, and disease-modifying approaches.

IGC Pharma matters less for current scale — it is a micro-cap with roughly $1.2 million in annual revenue — and more for its lead asset, IGC-AD1, a cannabinoid-based combination therapy that reported statistically significant Phase 2 interim results for Alzheimer's disease agitation (AAD), an indication with essentially one approved competing drug. The company funds its clinical program partly through sales of branded over-the-counter (OTC) wellness products made at its own facility, an unusual self-funding structure for a clinical-stage biotech.

---

1. Core Business Model & How They Work

IGC Pharma runs a dual-track model: a traditional FDA drug-development pipeline layered on top of a small, cash-generating consumer wellness products business that helps offset trial costs.

[ Preclinical Candidate Selection ] ➡️ [ In-House CRO-Run Clinical Trials ] ➡️ [ FDA Regulatory Pathway ] ➡️ [ Commercialization / Partnering ]
                                                      ▲
                                    [ OTC Wellness Product Sales ] ➡️ [ Funds Trial Costs ]

Key Operational Drivers

1. Internal Contract Research Organization (CRO): IGC Pharma runs its own clinical trial operations rather than outsourcing entirely to a third-party CRO, which management says materially lowers the cost of running trials like CALMA (the Phase 2 study for IGC-AD1).
2. Self-Funding via OTC Products: The company manufactures and sells branded OTC wellness and lifestyle products from its Vancouver, Washington facility, generating roughly $1.3 million of Life Sciences revenue in fiscal 2025 that helps offset R&D cash burn.
3. Capital Markets Access: Because the drug pipeline generates no product revenue, the company relies on equity issuance (private placements and an at-the-market offering program, which raised about $4.6 million in fiscal 2025) and a bank loan (an O-Bank facility, extended in mid-2025) to fund operations.
4. AI-Assisted Diagnostics: The company is developing MINT-AD, an AI/ML-based tool aimed at early detection of Alzheimer's-related cognitive impairment, a potential future licensing or data asset alongside the drug pipeline.

---

2. Product Portfolio & Pipeline

IGC Pharma's commercial OTC products are a minor, supporting revenue line; the real value drivers are the five Alzheimer's-focused drug candidates in the pipeline.

---

3. Competitive Landscape

IGC Pharma's most direct competitive comparison is in the narrow Alzheimer's-disease-agitation indication, where there is essentially one approved drug today.

         ALZHEIMER'S AGITATION COMPETITIVE POSITION
┌──────────────────────────────────────────────────────────┐
│ High          [Otsuka/Lundbeck — Rexulti]                 │
│  R             (FDA-approved, May 2023, incumbent)        │
│  E                                                          │
│  G                        [Axsome Therapeutics]            │
│  U                        (AXS-05, late-stage competitor)  │
│  L                                                          │
│  A      [IGC Pharma — IGC-AD1]                             │
│  T      (Phase 2, smaller/earlier)                          │
│  O                                                          │
│  R  Low                                                     │
│     └───────────────────────────────────────────────────► │
│       Early-Stage            FINANCIAL RESOURCES      Large│
└──────────────────────────────────────────────────────────┘

Competitors by Line

1. Alzheimer's Agitation (Lead Indication)

• Key Competitors: Otsuka/Lundbeck (Rexulti/brexpiprazole, the first and only FDA-approved AAD therapy as of May 2023), Axsome Therapeutics (AXS-05, dextromethorphan/bupropion combination).
• Dynamics: IGC Pharma is earlier-stage and far smaller than either incumbent, but is pursuing a distinct cannabinoid-based mechanism rather than competing head-on with repurposed CNS drugs.

2. OTC Wellness Products

• Key Competitors: Established, much larger food, supplement, and skincare companies.
• Dynamics: IGC Pharma has no scale advantage here; this line exists primarily to generate cash flow to support the drug pipeline rather than to win category share.

---

4. Strategic Strengths & Risks

Strengths (The Moat, Such as It Is)

• Self-Funded Trial Infrastructure: Running trials through an in-house CRO and partially funding them with OTC product sales reduces reliance on dilutive financing relative to a typical pre-revenue biotech.
• Early Positive Signal in an Underserved Indication: Statistically significant interim Phase 2 data in AAD, an indication with only one approved drug, gives IGC-AD1 a real (if early and unconfirmed) data point.
• Patent Filings: The company reports a portfolio of patent applications (with some granted) across its drug candidates, providing at least some intangible-asset protection if candidates advance.

Strategic Risks

1. Binary Clinical Risk: Every pipeline asset is preclinical or Phase 2; a single trial failure (including final CALMA results, expected around Q4 2026 per company statements) could eliminate most of the company's underlying value.
2. Thin Cash Position Relative to Burn: The company posted a $7.1 million net loss in fiscal 2025 against roughly $1.2 million of annual revenue, and has historically relied on equity raises and a bank loan to bridge the gap — a structurally dilutive position for existing shareholders.
3. Discontinued Infrastructure Segment: The company previously ran a second, unrelated India-based infrastructure/construction segment that generated zero revenue in fiscal 2025 (down from $164K in fiscal 2024) and has since been folded away — a reminder that the company's history includes a materially different, now-abandoned business line.
4. Competitive and Resource Disadvantage: Competitors like Otsuka, Lundbeck, and Axsome have vastly greater financial and commercial resources to defend or expand their position in AAD.

---

5. Financial Overview

---

6. Summary Conclusion

IGC Pharma is best understood as a micro-cap, single-indication-focused clinical-stage biotech that happens to generate a small amount of real product revenue to help fund its trials — a structural choice that somewhat de-risks its cash runway relative to peers with zero revenue, but does not change the fact that its value is overwhelmingly tied to the outcome of IGC-AD1's Phase 2 CALMA trial in Alzheimer's-related agitation.

The company's narrowed fiscal 2025 net loss and reduced spending show some financial discipline, but the business remains a binary bet: positive, durable Phase 2/3 data in an indication with only one approved competitor (Rexulti) would be transformative, while a disappointing final readout (expected around Q4 2026) would leave a thinly capitalized company with a small OTC products business and little else to fall back on.